Pfizer Inc.

PFIZER INC. $25 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 7.5 billion; Market cap: $187.5 billion; Price-to-sales ratio: 3.0; Dividend yield: 3.5%; TSINetwork Rating: Above Average; www.pfizer.com) has agreed to buy NextWave Pharmaceuticals Inc.

This private company has developed Quillivant XR, a liquid drug that treats attention deficit/hyperactivity disorder (ADHD). Pfizer’s extensive marketing and distribution operations should help expand sales of Quillivant XR.

Based on future sales of this drug, this purchase could cost Pfizer a total of $700 million. That’s equal to 15% of the $4.7billion, or $0.62 a share, that it earned in the second quarter of 2012. The deal should close by the end of 2012.

...

Most stock markets have risen lately. But as always, they remain subject to unexpected downturns. Even so, the long-term outlook is for higher stock prices. One way to profit from rising markets is to add exchange traded funds (ETFs) that track major stock indexes to your portfolio. ETF’s trade on stock exchanges, just like stocks. Prices are quoted in newspaper stock tables and online. You must pay brokerage commissions to buy and sell ETFs, but their low management fees still give them a cost advantage over most mutual funds....

WINDSTREAM CORP. $9.59 (Nasdaq symbol WIN; Income Portfolio, Utilities sector; Shares outstanding: 588.0 million; Market cap: $5.6 billion; Price-to-sales ratio: 1.1; Dividend yield: 10.4%; TSINetwork Rating: Average; www.windstream.com) reported revenue of $1.5 billion in the quarter ended June 30, 2012, up 49.3% from $1.0 billion a year earlier. The gain is mainly due to its December 2011 purchase of PAETEC Holding Corp., which sells telecommunication services to businesses. Integration costs cut its earnings by 43.4%, to $54.7 million, or $0.09 a share, from $96.7 million, or $0.19 a share. As a result of this purchase, Windstream now gets 68% of its revenue from broadband services, up 2.5% from a year earlier. That’s helping it offset declining traditional phone revenue. The company feels that closing overlapping functions will save it $50 million in 2012 and $100 million by the end of 2014. That should let it keep paying quarterly dividends of $0.25 a share, for a 10.4% annualized yield....

PFIZER INC. $24 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 7.5 billion; Market cap: $180.0 billion; Price-to-sales ratio: 2.8; Dividend yield: 3.7%; TSINetwork Rating: Above Average; www.pfizer.com) plans to spin off its animal health subsidiary, which makes drugs for livestock and pets, as a separate, publicly traded company. As part of this plan, Pfizer will sell up to 20% of this business. The new company, which will be called Zoetis Inc., supplied 6% of Pfizer’s 2011 revenue of $67.4 billion.

Pfizer should complete the offering in the first half of 2013. After that, it will probably hand out its remaining shares in Zoetis to its own shareholders.

Pfizer is a buy.

...

GOOGLE INC., $677.14, Nasdaq symbol GOOG, recently completed its $12.5-billion purchase of cellphone maker Motorola Mobility Holdings. This week, the company announced a new plan to make Motorola Mobility more profitable. This initiative involves including cutting 20% of its workforce and closing 30 of its 90 plants. Motorola Mobility will also shift its focus from regular cellphones to more profitable products like smartphones and tablet computers. It may also sell its home TV business, which makes set-top boxes for cable companies. Google expects to pay $275 million in severance and other costs. That’s equal to 8% of the $3.35 billion, or $10.21 a share, that it earned in the three months ended June 30, 2012....

SPDR S&P 500 ETF $131.97 (New York symbol SPY; buy or sell through brokers; www.spdrs.com) holds the stocks in the S&P 500 Index, which consists of 500 major U.S. stocks that are chosen based on their market cap, liquidity and industry group.

The index’s highest-weighted stocks are Apple Inc., ExxonMobil, Microsoft, Procter & Gamble, Wells Fargo & Co., Johnson & Johnson, IBM, Chevron, General Electric, Pfizer Inc., Coca-Cola Co., Google and AT&T.

The fund’s expenses are just 0.10% of its assets.

...

STANLEY BLACK & DECKER INC., $63.31, New York symbol SWK, is considering selling its consumer-hardware and home-improvement operations. These businesses make bath fixtures and other home accessories under brands such as Baldwin, Kwikset and Price Pfister. Stanley acquired these operations as part of its merger with rival toolmaker Black & Decker Corp. in March 2010. The company could receive $1.5 billion from these sales. That’s equal to 14% of its $10.8-billion market cap. Stanley will probably use the cash to add to its lineup of industrial tools and security devices, including locks, automatic doors and gates....

Most stock markets are down lately due to investor worries about a potential eurozone breakup, sluggish U.S. growth and a slowdown in China. Still, the long-term outlook is positive. One way to profit from a rebound is to add exchange traded funds (ETFs) that track major stock market indexes to your portfolio. ETFs trade on stock exchanges, just like stocks. Prices are quoted in newspaper stock tables and online. You must pay brokerage commissions to buy and sell ETFs, but their low management fees still give them a cost advantage over most mutual funds....

Novo Nordisk A/S (ADR), $142.29, symbol NVO on New York (Shares outstanding: 452.5 million; Market cap: $64.4 billion; www.novonordisk.com), is a major Denmark-based producer of diabetes-care products, including insulin. It also makes products for hormone replacement therapy and treating coagulation disorders. The company controls 50% of the global insulin market. It gets 40% of its sales from North America, followed by the European Union, 29%; Japan and Korea, 9%; China, 8%; and other regions, 14%. Novo’s shares have moved up since late last year on higher profits and sales....

Drug makers should see strong gains over the next few years, particularly due to the aging population. However, they still face challenges. For example, they must continually invest large sums to develop new drugs as patents expire on older ones. New drugs can also take years to win regulatory approval. As well, the pharmaceutical business is extremely competitive, and new, more effective products could come along at any time. To cut your risk, we recommend that you focus on leaders like Pfizer. The company recently lost the exclusive rights to its top-selling Lipitor cholesterol drug, but it has plenty of other promising products on the horizon. Its strong balance sheet is also helping it increase its research spending and buy other drug makers. PFIZER INC. $23 (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 7.5 billion; Market cap: $172.5 billion; Price-to-sales ratio: 2.5; Dividend yield: 3.8%; TSINetwork Rating: Above Average; www.pfizer.com) is the world’s largest pharmaceutical drug maker. Its top-selling brands include Lipitor (for high cholesterol), Lyrica (epilepsy), Celebrex (arthritis pain), Viagra (erectile dysfunction), Xalatan (glaucoma), Norvasc (hypertension) and Zyvox (bacterial infections). The company is also the world’s fifth-largest maker of over-the-counter drugs. Its major brands include Advil (pain relief), Centrum (vitamins) and Robitussin (cough syrup)....